SILO PHARMA, INC. Increase (Decrease) in Prepaid Expense
SILO PHARMA, INC. (SILO) reported Increase (Decrease) in Prepaid Expense of $29.70 thousand for the 9-month period ending 2023-09-30, per its 10-Q filed 2023-11-13.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInPrepaidExpense · last filed 2023-11-13
- SILO PHARMA, INC. increase (decrease) in prepaid expense for the quarter ending 2023-09-30 was -$20.37K, a 103.92% decline year-over-year.
- SILO PHARMA, INC. increase (decrease) in prepaid expense for the quarter ending 2023-06-30 was -$50.70K.
- SILO PHARMA, INC. increase (decrease) in prepaid expense for the quarter ending 2023-03-31 was $100.77K, a 44.64% increase year-over-year.
- SILO PHARMA, INC. increase (decrease) in prepaid expense for the quarter ending 2022-12-31 was -$537.01K.
- SILO PHARMA, INC. increase (decrease) in prepaid expense for fiscal 2022 was -$55.34K, a 242.39% decline from fiscal 2021.
- SILO PHARMA, INC. increase (decrease) in prepaid expense for fiscal 2021 was $38.86K, a 73.14% decline from fiscal 2020.
- SILO PHARMA, INC. increase (decrease) in prepaid expense for fiscal 2020 was $144.66K.
| Period end | Increase (Decrease) in Prepaid Expense 3 month | Increase (Decrease) in Prepaid Expense 3 month as first filed | Increase (Decrease) in Prepaid Expense 6 month | Increase (Decrease) in Prepaid Expense 6 month as first filed | Increase (Decrease) in Prepaid Expense 9 month | Increase (Decrease) in Prepaid Expense 9 month as first filed | Increase (Decrease) in Prepaid Expense 12 month |
|---|---|---|---|---|---|---|---|
| 2023-09-30 | -$20.37K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | -$71.07K derived: sum of 2 quarters · filed 2023-11-13 | $29.70K 10-Q · filed 2023-11-13 | -$507.31K derived: sum of 4 quarters · filed 2023-11-13 | |||
| 2023-06-30 | -$50.70K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-11 | $50.07K 10-Q · filed 2023-08-11 | -$486.94K derived: sum of 3 quarters · filed 2023-08-11 | $33.04K derived: sum of 4 quarters · filed 2023-11-13 | |||
| 2023-03-31 | $100.77K 10-Q · filed 2023-05-12 | -$436.24K derived: sum of 2 quarters · filed 2023-05-12 | $83.74K derived: sum of 3 quarters · filed 2023-11-13 | -$24.23K derived: sum of 4 quarters · filed 2023-11-13 | |||
| 2022-12-31 | -$537.01K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-24 | -$17.03K derived: sum of 2 quarters · filed 2023-11-13 | -$125.00K derived: sum of 3 quarters · filed 2023-11-13 | -$55.34K 10-K · filed 2023-03-24 | |||
| 2022-09-30 | $519.98K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | $412.01K derived: sum of 2 quarters · filed 2023-11-13 | $481.68K 10-Q · filed 2023-11-13 | $404.95K derived: sum of 4 quarters · filed 2023-11-13 | |||
| 2022-06-30 | -$107.97K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-11 | -$38.30K 10-Q · filed 2023-08-11 | -$115.03K derived: sum of 3 quarters · filed 2023-08-11 | -$63.49K derived: sum of 4 quarters · filed 2023-08-11 | |||
| 2022-03-31 | $69.67K 10-Q · filed 2023-05-12 | -$7.06K derived: sum of 2 quarters · filed 2023-05-12 | $44.48K derived: sum of 3 quarters · filed 2023-05-12 | -$1.39K derived: sum of 4 quarters · filed 2023-05-12 | |||
| 2021-12-31 | -$76.72K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-24 | -$25.18K derived: sum of 2 quarters · filed 2023-03-24 | -$71.05K derived: sum of 3 quarters · filed 2023-03-24 | $38.86K 10-K · filed 2023-03-24 | |||
| 2021-09-30 | $51.54K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $5.67K derived: sum of 2 quarters · filed 2022-11-10 | $115.59K 10-Q · filed 2022-11-10 | $28.12K 10-Q · filed 2021-11-10 | $142.90K derived: sum of 4 quarters · filed 2022-11-10 | ||
| 2021-06-30 | -$45.87K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-01 | $64.05K 10-Q · filed 2022-08-01 | $29.58K 10-Q · filed 2021-08-13 | $91.36K derived: sum of 3 quarters · filed 2022-08-01 | |||
| 2021-03-31 | $109.91K 10-Q · filed 2022-05-13 | $19.38K 10-Q · filed 2021-05-17 | $137.23K derived: sum of 2 quarters · filed 2022-05-13 | ||||
| 2020-12-31 | $27.32K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-28 | $144.66K 10-K · filed 2022-03-28 | |||||
| 2020-09-30 | $117.35K 10-Q · filed 2021-11-10 | ||||||
| 2018-09-30 | -$21.90K 10-Q · filed 2018-11-14 | ||||||
| 2017-09-30 | -$22.27K 10-Q · filed 2018-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| Sunshine Biopharma Inc. (SBFM) | $0.003B | ||
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Aptevo Therapeutics Inc. (APVO) | United States | $0.003B | |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |